Roche
While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.
Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial
The SKYSCRAPER-01 trial of tiragolumab plus Tecentriq will continue to assess how the combination impacts PD-L1-positive advanced NSCLC patients' overall survival.
Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials
MPAACT members will share trial data, aiming to standardize measurable residual disease as a surrogate endpoint for overall survival and speed up drug development. Â
Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members
The organization of pharmaceutical and biotechnology firms aims to increase access to genomic testing for cancer patients.
Roche, Bristol Myers Squibb Partner on Digital Pathology Algorithms, Assays for Cancer Diagnosis
Under the collaboration, Roche is developing an artificial intelligence-based image analysis algorithm to help pathologists interpret its Ventana PD-L1 (SP142) Assay.